Atea Pharmaceuticals (AVIR) CMO reports RSU vesting, share sale and 173,500-share option grant

Rhea-AI Filing Summary

Atea Pharmaceuticals Chief Medical Officer Maria Arantxa Horga reported equity compensation activity involving common stock, restricted stock units (RSUs), and stock options. On January 31, 2026, 41,533 RSUs from a 124,600-unit grant and an additional 9,750 performance-based RSUs vested and were converted into common shares, after which no RSUs remained outstanding from these grants.

On the same date, 51,283 shares of common stock were acquired through an option or RSU-related transaction, and 16,073 shares of common stock were disposed of at $4.24 per share, leaving 96,086 common shares beneficially owned directly. Horga also received a new stock option for 173,500 shares at an exercise price of $4.24, vesting in 48 equal monthly installments starting after January 31, 2026 and becoming fully vested on January 31, 2030.

Insider Trade Summary

51,283 shares exercised/converted

Mixed 5 txns

Insider Horga Maria Arantxa

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	41,533	$0.00	--
Exercise	Restricted Stock Units	9,750	$0.00	--
Grant/Award	Stock Option (Right to Buy)	173,500	$0.00	--
Exercise	Common Stock	51,283	$0.00	--
Tax Withholding	Common Stock	16,073	$4.24	$68K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Stock Option (Right to Buy) — 173,500 shares (Direct); Common Stock — 112,159 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The original grant of 124,600 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horga Maria Arantxa

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		51,283	A	(1)	112,159	D
Common Stock	01/31/2026		F		16,073	D	$4.24	96,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/31/2026		M			41,533	(2)	(2)	Common Stock	41,533	$0	0	D
Restricted Stock Units	(1)	01/31/2026		M			9,750	(3)	(3)	Common Stock	9,750	$0	0	D
Stock Option (Right to Buy)	$4.24	01/31/2026		A		173,500		(4)	01/30/2036	Common Stock	173,500	$0	173,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The original grant of 124,600 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

3. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

4. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Maria Arantxa Horga	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Atea Pharmaceuticals (AVIR) report for its Chief Medical Officer?

Atea Pharmaceuticals reported multiple equity transactions for Chief Medical Officer Maria Arantxa Horga. These included RSU vesting into common stock, the acquisition and disposition of common shares, and the grant of a sizable new stock option on January 31, 2026.

How many Atea Pharmaceuticals (AVIR) shares does the CMO own after this Form 4?

After the reported transactions, the Chief Medical Officer directly owns 96,086 shares of Atea Pharmaceuticals common stock. This figure reflects both the acquisition of 51,283 shares and the disposition of 16,073 shares on January 31, 2026.

What new stock option was granted to the Atea Pharmaceuticals (AVIR) CMO?

The Chief Medical Officer received a new stock option for 173,500 Atea Pharmaceuticals common shares. The option has a stated exercise price of $4.24 per share and vests in 48 equal monthly installments, becoming fully vested on January 31, 2030.

What happened to the restricted stock units (RSUs) in this Atea Pharmaceuticals (AVIR) filing?

RSUs totaling 41,533 units from a 124,600-unit grant and 9,750 performance-based RSUs vested on January 31, 2026. Each RSU represented a right to receive one common share, and following these transactions, zero RSUs from these grants remained outstanding.

At what price were Atea Pharmaceuticals (AVIR) shares disposed of in this Form 4?

16,073 shares of Atea Pharmaceuticals common stock were disposed of at a price of $4.24 per share. This transaction occurred on January 31, 2026 and was reported using transaction code “F” for the non-derivative common stock.

Over what period does the new Atea Pharmaceuticals (AVIR) stock option vest for the CMO?

The new 173,500-share stock option vests over 48 equal monthly installments after January 31, 2026. According to the filing, the option becomes fully vested and exercisable on January 31, 2030, subject to its stated vesting schedule.